Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration‐approved drugs

Abstract

Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.